ClinicalTrials.gg

Program

anvatabart opadotin

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 2, since Mar 18, 20214 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson31 open or runningphase 2since Mar 18, 2021Aug 14, 2017Dec 2026phase 2 · NCT04829604
Zhejiang Medicine10 open or runningphase 1since Jun 22, 2015Jun 22, 2015none ahead
  • Named in Johnson & Johnson’s own pipeline as JNJ-0683 (ARX788), phase 2, as of Oct 13, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 22, 2015First study: phase 1 study in Breast NeoplasmsNew to Zhejiang MedicineZhejiang Medicine · NCT02512237 · 9 enrolled · Australia, New Zealand
  2. Aug 14, 2017Johnson & Johnson’s first study: phase 1 study in Breast NeoplasmsNew to Johnson & JohnsonJohnson & Johnson · NCT03255070 · 106 enrolled · United States, Australia
  3. Mar 18, 2021Phase 2 study in Breast NeoplasmsJohnson & Johnson · NCT04829604 · 72 enrolled · United States, Australia, South Korea
  4. Sep 3, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05041972 · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Breast NeoplasmsJohnson & Johnson · NCT04829604

TargetBeta

“An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMA…”NCIt, read by Claude

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05041972Carcinoma, Non-Small-Cell Lung · United States2WithdrawnJohnson & JohnsonApr 20, 20220
NCT04829604Breast Neoplasms · United States, Australia, South Korea2Active, not recruitingJohnson & JohnsonDec 202672
NCT03255070Breast Neoplasms · United States, Australia1CompletedJohnson & JohnsonSep 13, 2023106
NCT02512237Breast Neoplasms · Australia, New Zealand1TerminatedZhejiang MedicineJan 20179

How it is read

Names in the registry

  • “ARX788”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.